NK-1 Antagonism of SLV317 in Humans

• Status: Completed
• Trial end date: 2003-11-01

Summary

The primary objective is to determine the effect of a single oral dose of 250 mg SLV 317 on substance P-induced venodilation in the hand vein of healthy male volunteers as compared to placebo.

• Phase: Phase 1

Details

• Lead Sponsor: Heidelberg University